Literature DB >> 11567229

MIB-1 (Ki-67), p53, estrogen receptor, and progesterone receptor expression in uterine smooth muscle tumors.

K Mittal1, R I Demopoulos.   

Abstract

The diagnosis of benign, uncertain malignant potential, and malignant uterine smooth muscle tumors depends on mitotic counts, nuclear atypia, and other morphologic features. This study was undertaken to evaluate the utility of selected immunohistochemical markers in differentiating these tumors. Fifteen cases of cellular leiomyoma, 7 cases of smooth muscle tumor of uncertain malignant potential (STUMP), and 12 cases of leiomyosarcoma were immunostained for MIB-1 (Ki-67), p53, estrogen receptor and progesterone receptor (PR) using monoclonal antibodies and the avidin-biotin-peroxidase method. The percentage of cells stained was subjectively assessed to the nearest 5%. One percent was used for rare positive cells. MIB-1 expression of > or =15% was seen in 11 and expression of p53 in > or =15% cells was present in 5 of 12 leiomyosarcomas. MIB-1 and/or p53 expression of >15% was seen in all 12 leiomyosarcomas but in none of the 7 STUMP or 15 cellular leiomyomas. PR was absent in 10 of 12 leiomyosarcomas but present in 7 of 7 STUMP and 14 of 15 cellular leiomyomas. MIB-1 of 5% to 10% was seen in 6 of 7 STUMP but in only 1 of 15 cellular leiomyomas. MIB-1, p53, and PR are useful in differentiating leiomyosarcoma from STUMP and cellular leiomyoma. MIB-1 is useful in distinguishing STUMP from cellular leiomyomas. Copyright 2001 by W.B. Saunders Company

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11567229     DOI: 10.1053/hupa.2001.27113

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  19 in total

1.  Analysis of molecular cytogenetic alterations in uterine leiomyosarcoma by array-based comparative genomic hybridization.

Authors:  Mohammad Raish; Mohsin Khurshid; Mushtaq Ahmad Ansari; Pankaj Kumar Chaturvedi; Su-Mi Bae; Jang Heub Kim; Eun Kyung Park; Dong Chun Park; Woong Shick Ahn
Journal:  J Cancer Res Clin Oncol       Date:  2012-03-15       Impact factor: 4.553

2.  A small-molecule inhibitor targeting the mitotic spindle checkpoint impairs the growth of uterine leiomyosarcoma.

Authors:  Weiwei Shan; Patricia Y Akinfenwa; Kari B Savannah; Nonna Kolomeyevskaya; Rudolfo Laucirica; Dafydd G Thomas; Kunle Odunsi; Chad J Creighton; Dina C Lev; Matthew L Anderson
Journal:  Clin Cancer Res       Date:  2012-04-25       Impact factor: 12.531

3.  An immunohistochemical analysis of stathmin 1 expression in uterine smooth muscle tumors: differential expression in leiomyosarcomas and leiomyomas.

Authors:  Mary-Margaret L Allen; Jonathan J Douds; Sharon X Liang; Mohamed M Desouki; Vinita Parkash; Oluwole Fadare
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

4.  Ki-67 expression in pulmonary tumors.

Authors:  Lucian R Chirieac
Journal:  Transl Lung Cancer Res       Date:  2016-10

5.  CREPT expression correlates with poor prognosis in patients with retroperitoneal leiomyosarcoma.

Authors:  Yaoguang She; Jiao Liang; Lin Chen; Ying Qiu; Na Liu; Xudong Zhao; Xiaohui Huang; Yinyin Wang; Fangli Ren; Zhijie Chang; Peiyu Li
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

6.  The selected biomarker analysis in 5 types of uterine smooth muscle tumors.

Authors:  Qing Zhang; Margaux Jenna Kanis; Julianne Ubago; Dachao Liu; Denise M Scholtens; Anna E Strohl; John R Lurain; Shohreh Shahabi; Beihua Kong; Jian-Jun Wei
Journal:  Hum Pathol       Date:  2017-12-16       Impact factor: 3.466

7.  Additional value of 16α-[18F]fluoro-17β-oestradiol PET for differential diagnosis between uterine sarcoma and leiomyoma in patients with positive or equivocal findings on [18F]fluorodeoxyglucose PET.

Authors:  Yoshio Yoshida; Yasushi Kiyono; Tetsuya Tsujikawa; Tetsuji Kurokawa; Hidehiko Okazawa; Fumikazu Kotsuji
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-06-08       Impact factor: 9.236

Review 8.  Practical issues in uterine pathology from banal to bewildering: the remarkable spectrum of smooth muscle neoplasia.

Authors:  Esther Oliva
Journal:  Mod Pathol       Date:  2016-01       Impact factor: 7.842

9.  Uterine smooth muscle tumors of uncertain malignant potential: a case presentation.

Authors:  Kazım Gezginç; Fatma Yazici; Lema Tavli
Journal:  Int J Clin Oncol       Date:  2011-01-12       Impact factor: 3.402

10.  Immunohistochemical studies on uterine carcinosarcoma, leiomyosarcoma, and endometrial stromal sarcoma: expression and prognostic importance of ten different markers.

Authors:  Riitta Koivisto-Korander; Ralf Butzow; Anna-Maija Koivisto; Arto Leminen
Journal:  Tumour Biol       Date:  2010-12-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.